Abstract 1986P
Background
To date no specific evidence exists on the impact of COVID-19 in pts with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and chemotherapy on COVID-19 morbidity and mortality in this specific population.
Methods
We described COVID-19 morbidity and mortality among pts with STS across “Omicron” (15/12/21-31/01/22), “Pre-vaccination” (27/02/20-30/11/20) and “Alpha-Delta” phase (01/12/20-14/12/21) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were described according to the SARS-CoV-2 vaccination status, whilst the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.
Results
Out of 3820 pts, 97 pts with STS were included. The median age at COVID-19 diagnosis was 56 years, with 65 pts (67%) aged <65 years old and 65 pts had low comorbidity burden (67%). In total, 36 pts were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications and 32.3% of hospitalizations due to COVID-19. CFR28 (29,5%, 21.4%, 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated pts demonstrated numerically improved CFR28 (16.7% vs 27.7%) and COVID-19 morbidity compared with unvaccinated pts. Pts who were on chemotherapy experienced comparable CFR28 (19.4% vs 26.0%, p=0.4803), hospitalizations (50.0% vs 44.4%, p=0.6883), complication rates (30.6% vs 34.0%, p=0.7381) and oxygen therapy requirement (28.1% vs 40.0%, p=0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis.
Conclusions
This is the first study to demonstrate the time-dependent improvement of COVID-19 outcomes in pts with STS. Exposure to chemotherapy does not impact on COVID-19 morbidity/mortality and SARS-CoV-2 vaccination confers protection against adverse outcome from COVID-19 in this patient population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15